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Over 90% of PDD patients show at least one neuropsychiatric symptom (NPS); in the 60–70% two or more NPS are present. Their
incidence is important in terms of prognosis and severity of pathology.However, among all NPS, apathy is often themost disturbing,
associated with greater caregiver’s burden. Similar to other NPS, apathy may be due to a dysfunction of the nigrostriatal pathway,
even though, not all the PD patients become apathetic, indicating that apathy should not entirely be considered a dopamine-
dependent syndrome, and in fact it might also be related to acetylcholine defects. Apathy has been treated in many ways, without
sure benefits; among these, Rivastigmine may present benefic properties. We present a series of 48 patients, suffering from PDD,
treated with Rivastigmine, and followed-up for one year; they have been devotedly studied for apathy, even though all the other
NPS disorders have been registered. Rivastigmine did not have a prolonged benefic effect on apathy, in our work, on the contrary
of what had been observed in the literature, probably due to the longer follow-up of our patients.
1. Introduction
Behavior and cognitive symptoms are common in Parkinson’s
Disease (PD) and in Parkinson’s Disease Dementia (PDD)
[1–6]. As well pointed out by a recent study [7], 90% of
PDD patients showed at least one neuropsychiatric symptom
(NPS) and a percentage up to 60–70% two or more NPS
[8]; NPS are important predictive factors for prognosis,
institutionalization, and overall mortality [9–13]. There is
no clinical consensus on how to treat NPS; antipsychotics
drugs are widely employed, but they should be used only
for small amount of time, and they are recommended to
treat hallucinations, delusions, and aggressiveness. Major
warning has been given by FDA to atypical neuroleptics [8]
and the American Geriatric Society (AGS) Beers consensus
criteria for safemedication use in the elderly [14] recommend
avoiding antipsychotics to treat NPS of dementia due to the
increased mortality and CVAE risk [14, 15]. Cholinesterase
and butirrylcholinesterase inhibitors and NMDA antagonists
have been used to treat primary cognitive disturbance in PDD
[16], but there are some data, which give reason for their
benefits also in the management of NPS [17–21].
However, among all the NPS, one of the most intriguing
(for the complicate pathophysiological mechanism underly-
ing it) [22] and one of the most disturbing (for caregivers
and for patients) is apathy. The presence of apathy has
been associated with greater cognitive impairment [[23–
27]; see data in [22]], and its prevalence in PDD varies
between 16.5% and 51%, depending upon the instrument
for assessment and on the samples examined [28–30]. It
has been hypothesized that dysfunction of the nigrostriatal
pathway might be involved in the pathophysiology of apathy
in PD, [29], confirmed by functional connectivity study
which documented a conspicuous impairment of striatal and
ventrolateral prefrontal regions connections [31]. Data are
not univocal, since two other studies [32, 33] did not find
out any structural differences when comparing apathetic to
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nonapathetic PD patients, after applying appropriate correc-
tion for multiple comparisons [34].
To be precise, the extension of brain networks involved in
apathy in PDD is enormous, and many other neuroimaging
and functional studies indicate different brain areas involve-
ment, not only nigrostriatal pathways [data and literature in
[22]] documented it. Reijnders et al. [25] found an association
between higher apathy and lower gray matter density in
the bilateral inferior frontal gyrus and precentral gyrus, in
the bilateral inferior parietal gyrus, and right precuneus,
confirmed by Skidmore et al. [35], who showed that the
severity of apathywas best predicted by a greater sufferance of
the right middle orbitofrontal cortex and bilateral subgenual
cingulate cortex, of the left supplementary motor cortex,
and of the left inferior parietal lobule and left fusiform
gyrus [35]. (FDG) PET-studies specifically found a positive
correlation of apathy and cerebral metabolism during rest in
the right middle frontal gyrus, right inferior frontal gyrus,
left anterior insula [26], bilateral orbitofrontal lobes and
bilateral anterior cingulate [32], and left posterior cingulate
cortex [26]. Much more interesting is that not all the PD
patients become apathetic, indicating that apathy should not
entirely be considered a dopamine-dependent syndrome in
PD, and is in fact present even in not-purely dopaminergic
alterations [11, 36, 37]. As strongly pointed out by Kos et
al., [34] an inverse correlation between catecholaminergic
binding potential, indicative of a specific combined loss of
dopamine and noradrenaline innervation, and apathy was
found in the bilateral ventral striatum in an exploratory
resting-state analysis in PD [38]. Some studies tried to involve
acetylcholine in driving motivation and its lack related to
apathy [39].
Apathy has been treated in many different ways [17, 40–
42]. Some recently published studies [5, 6] suggested some
benefic properties of Rivastigmine on this NPS symptom too,
in complete accordance with the results obtained by Devos et
al. [17].
We present a series of patients, suffering from PDD,
treated with Rivastigmine, and devotedly studied for apathy,
within a complex sequence of NPS disorders; we did not have
the same successful results showed by the previous studies; we
discuss the results, trying to give pathological explanation to
a different possible mechanism outstanding apathy in PDD.
2. Materials and Methods
50 patients diagnosed with PDD, from 1 December 2010
up to 31 December 2013, referring to the Neurological Unit
Research of Trieste, were enrolled.
The diagnosis was based on UK PD Society Brain Bank
clinical diagnostic criteria and clinical diagnostic criteria for
probable PDD [43–45]. Data from a physical and neuro-
logical examinations, laboratory tests, and brain magnetic
resonance imaging (or CT for 6 patients, claustrophobic and
therefore not possible for them to attendMRI) were obtained.
Patients with a history of stroke or brain hemorrhage or other
psychiatric disorders, atypical PD, or secondary Parkinson-
ism have not been enrolled for this study.
The patients must completely fulfill the criteria for prob-
able PDD, as presented by Goetz et al. [45]: core features
must be present, as well as a typical profile of impaired
attention, fluctuation of executive functions, an impairment
in visuospatial functions, or impaired free recall; it should
be associated with at least one behavioral symptom (such
as apathy, depression, and anxiety). Patients must fulfill the
diagnostic rating sheet for probable PDD, with a history
of PD, with a PD disease developed before dementia, with
MMSE’ scores less than 26,with an impairment inADLs,with
impaired cognition for the 4 items (sevens backwards; lexical
fluency; MMSE pentagons; 3-word recall), with absence of
major depression; absence of delirium; and absence of other
neuropsychiatric diseases [46].
All patients were diagnosed for the first time as PDD,
upon enrollment in this study.
All patients were on antiparkinsonian medications.
The equivalent daily dose of levodopa was calculated
as the international standard converting measure [47] as
follows: dose of levodopa plus dose of dopamine-agonists
multiplied by equivalents (= 1 × levodopa dose + 0.75 ×
controlled release dose + 0.33 × entacapone + 20 × ropinirole
dose + 100 × pramipexole + 10 × selegiline + 1 × amantadine)
[47]. Each caregiver’s patient gave informed consent for
participation before entry. All procedures complied with
ethical standards for human investigations and the principles
of the Declaration of Helsinki.
2.1. Outcome Measures. This was a prospective, longitudinal,
open-label, observational, single center, 12-month clinical
trial on the effect of Rivastigmine for improving BPSD, with
particular reference to apathy. Baseline second level testing
data were obtained before starting Rivastigmine, which has
been titrated to all patients for eight weeks. All subjects
were administered a maintenance dose of Rivastigmine for
12 months. The main outcomes of the study were as follows:
(1) Global performance was assessed using the Mon-
treal Cognitive Assessment (MoCA) [48–50]; the
test comprises 6 parts, which have been adminis-
tered in extenso (memory recall-5 scores; visuospatial
construction 4 scores; executive functions 4 scores;
attention and working memory 6 scores; language
5 scores; orientation: 6 scores). We considered the
results as a whole, and not by subscores. The most
significant parts, however, are attention, executive
function, and visuospatial construction.
(2) Executive functions, attention, judgment, and analog-
ical reasoning were assessed by Frontal Assessment
Battery (FAB) [51].
(3) Apathy was assessed by the Clinician/Researcher
Rated Version of the Apathy Evaluation Scale (AES-
C) and the parallel Self-Report Version of the same
instrument (AES-S) [52]; total score ranges from 18 to
72 points (higher score indicates more severe apathy).
The cutoff score ≥ 37 was used to divide apathetic
from nonapathetic patients. In the present study, we
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considered to be apathetic a patient who showed a
total AES-S score ≥37.
(4) Global behavioral symptoms were assessed by the
Neuropsychiatric Inventory, NPI [53]; symptom fre-
quency was rated on a scale of 1 to 4 (1 = less than
once a week; 2 = once a week; 3 = several times
a week; 4 = everyday), and severity was rated on a
scale of 1 to 3 (1 = mild; 2 = moderate; 3 = severe).
A composite score ranging from 1 to 12, defined as
the product of frequency and severity, was calculated.
The important aspect of caregiver distress was also
recorded and scored for each neuropsychiatric symp-
tom complex (as the study by Oh et al., 2015-A) [6].
The caregiver was asked to rate their own emotional
or psychological distress caused by each symptom on
a scale of 0 to 5 (0 = no distress; 1 = minimal; 2 =
mild; 3 = moderate; 4 = moderately severe; 5 = very
severe). A total caregiver distress score was obtained
by summing the individual scores on the 12 items (as
the study by Oh et al., 2015-A [6]).
2.2. Statistical Analyses. Statistical analyses were performed
using the Statistical Package for the Social Sciences (SPSS,
version 16.0). Within group changes from baseline to 12
months were tested using the Wilcoxon Signed Ranks test.
This was done for the overall scores for each efficacy variable.
In addition, subanalyses of Spearman’s Rho correlation
and 2-tailed analyses were performed between behavioral
data obtained using the NPI, the FAB scores, and apathy
scores.
Results are presented as mean changes from baseline
with standard deviations, and 𝑝 values are presented where
appropriate.
3. Results
Of the 50 patients enrolled, 2 abandoned the study, so 48
patients have been fully studied and followed for 12 months
(28 males, 20 women). They have been diagnosed as PDD
in accordance with the complete fulfillment of the eight
items of the diagnostic rating sheet for probable PDD, as
recommended by the Movement Disorder Task Force [46],
and their mean scores have been reported in Table 1. Their
mean age is 70.4 ± 2.34 years old; their mean educational
level is 8.5 ± 2.5 years of school attendance. The mean L-
dopa equivalent dosage was 660 ± 130.5mg/day. 42 patients
received dopamine-agonists, 17 entacapone during their cure.
Patients have been followed for a mean period of three
years (2.5 ± 0.6 years) for motor disturbances, and they
have been diagnosed as PDD during the first visit in our
Unit. They have never assumed anticholinesterase inhibitors
before our diagnosis. Patients were titrated in threemonths to
receive the mean patch dose of transdermal Rivastigmine of
9.5mg/24 hrs. The most salient side effects at every titration
are nausea and disequilibrium; nobody refused the therapy
and abandoned the study for conspicuous side effects. Heart
frequency and blood pressure are measured at each visit but
Table 1: Cognitive parameters. Values are mean (SD). NS = not
significant. ∗MMSE corrected for the adjustments according to age
and education.
Recruitment
MMSE∗ 23.7 (0.6)
Pill Questionnaire 2.1 (0.2)
Attention, months reversed 3.1 (0.4)
Lexical fluency 8.2 (0.7)
MMSE pentagons 0.1 (0.1)
3-word recall 2.1 (0.3)
GDS-15 3.6 (0.5)
the caregivers have been instructed to measure by themselves
at home three times a week.
Table 2 reproduced the summary of the most salient
cognitive aspects, compared with a Wilcoxon Signed Rank
test (12 months versus baseline).
Tables 3, 4, and 5 represent the behavior aspect resumed
by NPI subscores, in order of their prevalence in the studied
population, their relevance (the product of severity for
frequency), and the derived caregiver stress parameters (as
derived by the scores they gave).
Table 6 reflects a sum-up of the possible coexistence
of more than 1NPS for each patient, during the 12-month
follow-up.
Table 7 reflects the qualitative results of apathy evaluation,
as self-reported (AES-S) and clinically evaluated (AES-C).
We have considered as apathetic a patient with a score of
>37; all our patients satisfied the criteria, and we report the
differences, according to a Wilcoxon rank signed test from
the cutoff.
There is a slight, but significant decrease in global cogni-
tive functions and in frontal executive functions, as reported
in Table 2. From the very beginning, all the patients showed
behavior symptoms, as reported inTable 3; the first evaluation
indicates that 77%of patientsmanifested apathy, with a severe
impact on daily living (8, as the product of frequency ×
severity, maximum score 12), and with a severe relevance for
caregivers (4, in a scale from 0 to 5); the secondmore relevant
symptom is anxiety (54% of patients), with an important
impact in daily living (6, as the product of frequency ×
severity), and with a limited relevance for caregivers (2, in
a scale from 0 to 5); the third symptom is depression (46%
of patients), with a discrete impact in daily living (4, as the
product of frequency× severity), andwith a limited relevance
for caregivers (2, in a scale from 0 to 5); the fourth symptom
is hallucinations (42% of patients), with a limited impact on
daily living (2, as the product of frequency × severity) and
with a limited relevance for caregivers (1, in a scale from 0 to
5). It should be noted that all the other NPS symptoms have
been reported, within a limited number of patients, and with
limited consequences in daily living. Qualitative assessment
of apathy (AES-S and AES-C) is online with this report,
as shown in Table 7; as shown in Table 6, 25% of patients
showed only one NPS symptom; 42% showed two or more
NPS symptoms and 33% three or more. The mean total NPI
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Table 2: Cognitive parameters at baseline and at 12months.Values aremean (SD).NS=not significant. ∗MoCAare reported as raw scores, and
in square brackets corrected for the adjustments according to age and education expressed as years of schooling-Conti et al., 2015; Santangelo
et al., 2015.
Baseline 12 months
Within groups
(12months versus
baseline)
𝑝 value
MoCA∗ 24.1 (0.9) [22.01 (0.8)] 21.3 (0.2) [18.1 (0.7)] 𝑝 < 0.05
FAB total score 8.2 (0.5) 7.1 (1.3) 𝑝 < 0.05
Analogies 1.1 (0.2) 1.1 (0.6) 𝑝 < 0.05
Phonemic fluency 1.2 (0.2) 0.9 (0.5) NS
Motor series 2.1 (0.7) 1.6 (0.2) 𝑝 < 0.05
Contrast instructions 2.1 (0.8) 1.4 (0.5) 𝑝 < 0.05
Go/no-go 0.6 (0.5) 0.2 (0.4) 𝑝 < 0.05
Prehension behavior 1.1 (0.9) 0.9 (0.8) NS
Table 3: Baseline NPI results.
Subitems NPI Number of patients/48 (%) Frequency × severity Caregiver distress
hallucinations 20 (42%) 2 1
Delusions 10 (21%) 1 1
Agitation/aggression 5 (10%) 2 1
Dysphoria/depression 22 (46%) 4 2
Anxiety 26 (54%) 6 2
Irritability 7 (15%) 4 2
Disinhibition 2 (4%) 2 2
Euphoria 3 (6%) 2 2
Apathy 37 (77%) 8 4
Aberrant motor behavior 3 (6%) 2 2
Sleep behavior change 6 (12%) 4 3
Appetite change 2 (4%) 2 2
Table 4: 6-month NPI results; in the first and third rows it has been reported the within group comparison with baseline.
Subitems NPI
Number of patients/48 (%)
within groups
(6 months versus baseline)
Frequency × severity Caregiver distress
hallucinations 16 (33%) (𝑝 < 0.001) 2 1 (NS)
Delusions 7 (15%) (𝑝 < 0.05) 1 1 (NS)
Agitation/aggression 4 (8%) (NS) 2 1 (NS)
Dysphoria/depression 17 (35%) (𝑝 < 0.001) 3 1 (𝑝 < 0.05)
Anxiety 20 (42%) (𝑝 < 0.001) 4 1 (𝑝 < 0.05)
Irritability 4 (8%) (𝑝 < 0.001) 3 1 (𝑝 < 0.05)
Disinhibition 1 (2%) (𝑝 < 0.001) 2 1 (𝑝 < 0.05)
Euphoria 2 (4%) (NS) 2 1 (𝑝 < 0.05)
Apathy 30 (62%) (𝑝 < 0.001) 8 4 (NS)
Aberrant motor behavior 2 (4%) (NS) 2 2 (𝑝 < 0.05)
Sleep behavior change 4 (8%) (𝑝 < 0.001) 2 3 (𝑝 < 0.05)
Appetite change 1 (2%) (𝑝 < 0.001) 2 2 (𝑝 < 0.05)
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Table 5: 12-month NPI results. In the first and third rows it has been reported the within group comparison with baseline and with 6-month
results.
Subitems NPI
Number of patients/48 (%)
within groups
(12 months versus baseline)
(12 months versus
6months)
Frequency × severity
Caregiver distress
within groups
(12months versus baseline)
(12months versus
6months)
Hallucinations
15 (31%)
(𝑝 < 0.001)
(NS)
2
1
(NS)
(NS)
Delusions
8 (17%)
(𝑝 < 0.05)
(NS)
1
1
(NS)
(NS)
Agitation/aggression
3 (8%)
(NS)
(NS)
2
1
(NS)
(NS)
Dysphoria/depression
19 (40%)
(𝑝 < 0.05)
(NS)
3
1
(𝑝 < 0.05)
(NS)
Anxiety
21 (44%)
(𝑝 < 0.001)
(NS)
4
1
(𝑝 < 0.05)
(NS)
Irritability
1 (2%)
(𝑝 < 0.001)
(𝑝 < 0.001)
3
1
(𝑝 < 0.05)
(NS)
Disinhibition
0 (0%)
(𝑝 < 0.001)
(𝑝 < 0.001)
0
1
(𝑝 < 0.05)
(NS)
Euphoria
0 (0%)
(𝑝 < 0.001)
(𝑝 < 0.001)
0
1
(𝑝 < 0.05)
(NS)
Apathy
33 (69%)
(𝑝 < 0.05)
(NS)
8
8
(NS)
(NS)
Aberrant motor behavior
1 (4%)
(NS)
(NS)
1
1
(𝑝 < 0.05)
(NS)
Sleep behavior change
5 (10%)
(𝑝 < 0.001)
(NS)
3
2
(𝑝 < 0.05)
(NS)
Appetite change
1 (2%)
(𝑝 < 0.001)
(NS)
1
1
(𝑝 < 0.05)
(NS)
Table 6: A synopsis of the presence of a single or more than one NPS for each patient, during follow-up.
3 or more NPS
num pts/48 (%)
2 or more NPS
num pts/48 (%)
1 NPS
num pts/48 (%)
NPI baseline 16 (33%) 20 (42%) 12 (25%)
NPI 6 months 12 (25%) 26 (54%) 10 (21%)
NPI 12 months 8 (17%) 28 (58%) 12 (25%)
composite score at baseline was 39.4±12.1 and total caregiver
distress score was 24.6 ± 11.1.
At 6-month evaluation, all the patients presented behav-
ior symptoms, as reported in Table 4; the evaluation indicates
that 62% of patients manifested apathy (decrease within
group, 6 month versus baseline, with aWilcoxon rank signed
test, −7 ± 0.5, 𝑝 < 0.001), with a severe impact on daily living
(8, as the product of frequency × severity, maximum score
12), and with a severe relevance for caregivers (4, in a scale
from 0 to 5, not significant from baseline); the second more
relevant symptom remains anxiety (42% of patients; decrease
within group, 6months versus baseline, with aWilcoxon rank
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Table 7: Apathy scores, AES-C, clinician rated apathy evaluation
scale; AES-S, self-report rated apathy evaluation scale. Values are
mean (SD). NS = not significant. We report the differences from the
cutoff score.
Baseline
cutoff > 37
12- month
cutoff > 37
Within group
baseline/12
months
AES-S +16.3 (4.1) + 19.9 (2.1) NS
AES-C +15.5 (3.7) +21.5 (2.7) 𝑝 < 0.05
signed test: −6 ± 0.8, 𝑝 < 0.001), with a decreased impact
on daily living (4, as the product of frequency × severity),
and with a limited relevance for caregivers (1, in a scale from
0 to 5, 𝑝 < 0.05 versus baseline); the third symptom is
depression (35% of patients; decrease within group, 6 months
versus baseline, with a Wilcoxon rank signed test: −4 ± 0.9,
𝑝 < 0.001), with a modest impact on daily living (3, as the
product of frequency× severity), andwith a limited relevance
for caregivers (1, in a scale from 0 to 5, 𝑝 < 0.05); the
fourth symptom is hallucinations (33% of patients; decrease
within group, 6months versus baseline, with aWilcoxon rank
signed test: −4 ± 0.9, 𝑝 < 0.001), with a limited impact on
daily living (2, as the product of frequency × severity), and
with a limited relevance for caregivers (1, in a scale from 0
to 5, 𝑝 < 0.05). It should be noted that all the other NPS
symptoms have been reported, and caregivers reflect a relief
of their distress; nonsignificant results have been found for
agitation/aggression, euphoria, and aberrant motor behavior
parameters, but they had very limited consequences in daily
living and were minor cause of caregiver’ distress. Moreover,
as shown in Table 6, 21% of patients showed only one NPS
symptom; 54% showed two or more NPS symptoms and 25%
three ormore.Themean totalNPI composite score at baseline
was 33.1 ± 17.1 (according to a Wilcoxon Signed rank test,
within group, −6.3±5.0, 𝑝 < 0.05) and total caregiver distress
scorewas 16.7±7.1 (according to aWilcoxon Signed rank test,
within group, −5.9 ± 4.0, 𝑝 < 0.05).
At 12-month evaluation, all the patients presented behav-
ior symptoms, as reported in Table 5; results here have been
compared within groups (12 months versus baseline and 6
months versus baseline); there is a general stability of the
results; there is a slight decrease in the irritability scores,
associated with a decrease in the disinhibition scores and
in the euphoria scores (𝑝 < 0.001), in comparison with
the results obtained at 6-month evaluation; apathy increased,
up to 69% of patients (decrease within group, 12 month
versus baseline, with a Wilcoxon rank signed test (−4 ± 0.7,
𝑝 < 0.05)), with a severe impact on daily living (8, as the
product of frequency × severity, maximum score 12) and with
a severe relevance for caregivers (4, in a scale from 0 to 5,
not significant from baseline and from 6months); the second
more relevant symptom remains anxiety, increasing up to
44% of patients up to 6 months (decrease within group, 12
months versus baseline, with a Wilcoxon rank signed test
(−5 ± 0.8, 𝑝 < 0.05)), with a stable impact on daily living
(4, as the product of frequency × severity), but with a limited
relevance for caregivers (1, in a scale from 0 to 5, 𝑝 < 0.05
versus baseline, stable versus 6 month); the third symptom
is depression, rising up to 40% from 6-month evaluation
(decrease within group, 12 months versus baseline, with a
Wilcoxon rank signed test (−3±0.3,𝑝 < 0.05)), with amodest,
stable, impact on daily living (3, as the product of frequency
× severity), and with a limited relevance for caregivers (1, in
a scale from 0 to 5, 𝑝 < 0.05 versus baseline, stable versus
6 months); the fourth stable symptom is hallucinations (31%
of patients, decrease within group, 12 months versus baseline,
with aWilcoxon rank signed test (−5±0.4,𝑝 < 0.001)), with a
limited impact on daily living (2, as the product of frequency
× severity), and with a limited relevance for caregivers (1, in
a scale from 0 to 5, not significant versus baseline and versus
6-month evaluation). Moreover, as shown in Table 6, 25% of
patients showed only one NPS symptom; 58% showed two or
more NPS symptoms and 17% three or more. The mean total
NPI composite score at baseline was 28.7 ± 11.3 (according
to aWilcoxon Signed rank test, within group, versus baseline
−4.4 ± 5.8, 𝑝 < 0.05) and an increased total caregiver distress
score, which was 20.3 ± 6.2 (according to a Wilcoxon Signed
rank test, within group, +3.9 ± 1.1, 𝑝 < 0.05). Qualitative
assessment of apathy (AES-S and C) is online with this report,
as shown in Table 7 with a significant increase of AES-C, above
the cutoff scores (according to a Wilcoxon Signed rank test,
within group, versus baseline +6.2 ± 2.1, 𝑝 < 0.05).
Spearman’s rank correlation analyses (made at 12months)
indicated that there was a significant correlation, in both the
groups, between
(1) NPI high scores and caregiver’s distress (𝑟 = 0.78, 𝑝 <
0.01);
(2) NPI apathy score and AES-S and AES-C (𝑟 = 0.71,
𝑝 < 0.01 and 𝑟 = 0.78, 𝑝 < 0.01, respectively);
(3) FAB scores and apathy score (NPI and AES-C) (𝑟 =
0.75, 𝑝 < 0.01 for NPI subscore and 𝑟 = 0.79, 𝑝 <
0.01, for AES-C).
4. Discussion
This work shares many points with the most recent published
on the topic [5, 6, 42]; the principal and most significant of
them is that NPS are the most salient aspects of PDD intel-
lective disruption and the most relevant for their caregivers.
On the contrary of what merged from the other studies,
where depression and anxiety are the most cited NPS, in this
study we have found that apathy is the most constant NPS;
its impact for frequency and severity is heavy and constant in
the time and is onerous for the caregivers.
Rivastigmine works well and improves NPS symptoms,
reducing caregivers’ stress, in line with many other studies
[5, 6, 54], in PD psychosis [55], in AD [56, 57], and in
sVAD [20, 21] at the very beginning, and, in line with
what has been previously described, we assist a first-step
(6-month evaluation) global general amelioration of signs
and symptoms in NPS, with a relief of caregiver’s distress.
That concerns practically all the NPS, a part from agitation
and aberrant motor behavior; the results are so good to
Parkinson’s Disease 7
reflect on a significant decrease of NPI total score and an
effective decrease on caregiver’s burden. But even at this
point, apathy, in our cases, maintains its hard impact, and
for its frequency and severity it is related to caregiver’s stress.
Rivastigmine does not ameliorate that score. At 12-month
evaluation, results in our study differ, even more, from the
previous reported studies: there is a slight reduction of NPS
signs, as demonstrated by the comparison with baseline
results, but results are quite superimposable to what has been
revealed at 6-month evaluation. On the contrary, caregivers
burden increase significantly. That relates quite well with the
qualitative perceive of apathy, as demonstrated by AES-S
and AES-C, which remains stable from baseline throughout
the entire follow-up. So, we can conclude that Rivastigmine
might help for NPS symptoms in PDD, but its efficacy is
limited in time, varies for symptoms, and does not have
benefit for apathy in daily living.
Apathy increments in PDD the burden of the othermotor
and intellectual dysfunctions andworsens all the other behav-
ioral symptoms. As reported in many dedicated studies, apa-
thy is tightly related to PD or, better say, to a sufferance of the
nigrostriatal pathway [13, 29, 58, 59]. Functional connectivity
within the striatum and between striatal and ventrolateral
prefrontal regions has been demonstrated in support of those
studies, in patients with PD with high apathy compared to
low [31], but results are not univocal, as they have been
rejected by other studies [32, 33]. In general, many others
are the brain networks related to apathy in PD, extending
from the nigrostriatal up to frontal, cingulate, and limbic
areas, precuneus, parietal inferior lobule, and so on (see
data and literature in [22, 34]). If functional localization of
networks underlying apathy is uncertain, evenmore complex
is the neurochemical and pharmacological face.Hence, seem-
ing quite conclusive that basal forebrain, striatum, parietal,
and frontal cortex are strongly involved in apathy, three
major neurotransmitters should be taken into account for its
determination: acetylcholine, noradrenaline, and dopamine.
An inverse correlation between catecholaminergic binding
potential, indicative of a specific loss of dopamine and
noradrenaline innervation, and apathy in PD was found in
the bilateral ventral striatum [38]. But again, data are not so
certain and are verified by studies in AD patients, although
dopaminergic neurotransmission is thought to underline
many goal-directed behaviors including addiction, and there
is evidence for the efficacy of dopaminergic agents for apathy
in AD [60]; there was no association between dopamine
D2/D3 receptor density and apathy in AD [61]. We have no
data, at the moment, for the studies of D2-D3 concentrations
in PD or PDD with or without apathy.
Since many NPS respond to acetylcholinestease and
butyrrylcholinesterase inhibitors, it can be documented a
pivotal role of Ach in vivo. Rivastigmine works quite well,
at least at the very beginning for NPS, but not for apathy.
What seems highly probable is that in PDD there is a
very precarious equilibrium between dopamine and Ach
and that disequilibrium might potentiate the resistance of
specific symptoms such as apathy, probably determined by
the alteration of multineurotransmitters synaptic networks.
Our study has some strengths:
(1) We enrolled first-diagnosed PDD patients who began
Rivastigmine in our study and have been studied for
12 months.
(2) All the patients can be fully examined and have a
strenuous assistance of a caregiver, who is the other
actor of the study.
(3) We employed some similar method as those
described by Oh et al. (2015-A) [6] and implement
some other measures, but as Oh et al., [6] we strictly
surveyed the pharmacological intake of our patients
in order to avoid any other interference bias.
(4) All the patients have been supplied by transdermal
Rivastigmine patch.
However, our study has several weaknesses:
(1) It is a single center study, and the number of patients
is very small to infer definite results.
(2) It is an open-label and not blinded study.
(3) It has no pathological confirmation.
Data deriving from our study suggest that
(1) apathy should be considered from the very initial
phases of PD (and PDD) by devoted neuropsycholog-
ical instrument;
(2) multireceptor approach should be employed to treat
it, so many potential sites could be employed, such
as SSRI, NARI, dopaminergic agonists, and probably
modulating also Ach;
(3) apathy should be discussed with and explained to
patients and to caregivers: it might help to confront
it better;
(4) neurologists should think more overtly about apathy,
in order to understand it and possibly treat it; apathy
inside a specific disease, such as PD, or AD, or sVAD
might become something different. It must be said,
forwardly, that, as well as in AD, it seems difficult to
find a neurodegenerative complex clinical condition,
such as PDD, in which apathy is an isolated symptom.
AS in our study, even if devotedly constructed to
define it, apathy can coexist with other NPS, and
therefore, its anatomical and biochemical core could
be modified and worsened, by the interference of
many other neurochemical substrates, which under-
line opposite symptoms, such as anxiety, aggression,
and euphoria.
5. Conclusion
In conclusion, our study confirmed some results of many
other precedent studies, on the positive results of Rivastig-
mine for the reduction of NPS symptoms, but we are
more circumspect on its effect on apathy, suggesting that
polyvalent and multireceptor treatment should be desirable
and employed; larger, placebo-controlled studies should be
required to define, adequately combat, and give long-lasting
relief to such a difficult symptom, as apathy is.
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